| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
|
Harbeck, Nadia
|
|
|
17 |
3 |
p. 357-366
|
article
|
| 2 |
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
|
Kim, Seok Jin
|
|
|
17 |
3 |
p. 389-400
|
article
|
| 3 |
2016 ASCO Gastrointestinal Cancers Symposium
|
Landman, Allison
|
|
|
17 |
3 |
p. 282
|
article
|
| 4 |
Association between allergies and reduced risk of glioma
|
Burki, Talha Khan
|
|
|
17 |
3 |
p. e94
|
article
|
| 5 |
Atypical glandular cells and risk of cervical cancer
|
Burki, Talha Khan
|
|
|
17 |
3 |
p. e96
|
article
|
| 6 |
Benefits of pazopanib over sunitinib for renal cell carcinoma
|
Granovetter, Michael
|
|
|
17 |
3 |
p. e93
|
article
|
| 7 |
Chemotherapy-induced vomiting in children: some progress, more questions
|
Dupuis, L Lee
|
|
|
17 |
3 |
p. 264-265
|
article
|
| 8 |
Correction to Lancet Oncol 2016; 17: 266
|
|
|
|
17 |
3 |
p. e90
|
article
|
| 9 |
Counting the cost of end-of-life cancer care
|
Burki, Talha Khan
|
|
|
17 |
3 |
p. e91
|
article
|
| 10 |
DCIS and invasive interval breast cancer
|
Narod, Steven A
|
|
|
17 |
3 |
p. e87-e88
|
article
|
| 11 |
DCIS and invasive interval breast cancer
|
Foucar, Elliott
|
|
|
17 |
3 |
p. e87
|
article
|
| 12 |
DCIS and invasive interval breast cancer – Author's reply
|
Duffy, Stephen W
|
|
|
17 |
3 |
p. e88-e89
|
article
|
| 13 |
Deadpool: using pop culture for cancer advocacy
|
Lokody, Isabel
|
|
|
17 |
3 |
p. 285
|
article
|
| 14 |
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
|
Armstrong, Andrew J
|
|
|
17 |
3 |
p. 378-388
|
article
|
| 15 |
Extranodal natural killer T-cell lymphoma—new profiling, old tricks
|
Shustov, Andrei R
|
|
|
17 |
3 |
p. 271-273
|
article
|
| 16 |
FDA confronts opioid addiction and overdose deaths
|
Furlow, Bryant
|
|
|
17 |
3 |
p. e95
|
article
|
| 17 |
Framework for tackling paediatric chemotherapy drug shortages
|
Tanday, Sanjay
|
|
|
17 |
3 |
p. e93
|
article
|
| 18 |
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
|
Fujitani, Kazumasa
|
|
|
17 |
3 |
p. 309-318
|
article
|
| 19 |
HER2-positive breast cancer: is more treatment better?
|
Rugo, Hope S
|
|
|
17 |
3 |
p. 268-270
|
article
|
| 20 |
Immunomodulatory agents in mantle cell lymphoma
|
Dunleavy, Kieron
|
|
|
17 |
3 |
p. 262-263
|
article
|
| 21 |
Inadvisable breast and prostate cancer screenings in the USA
|
Granovetter, Michael
|
|
|
17 |
3 |
p. e92
|
article
|
| 22 |
Increase in illicit cigarette consumption in Brazil
|
Bagcchi, Sanjeet
|
|
|
17 |
3 |
p. e92
|
article
|
| 23 |
IRF4 SNP is predictive of melanoma subtypes
|
Granovetter, Michael
|
|
|
17 |
3 |
p. e96
|
article
|
| 24 |
Justifying vein resection with pancreatoduodenectomy
|
Barreto, Savio G
|
|
|
17 |
3 |
p. e118-e124
|
article
|
| 25 |
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
|
Trněný, Marek
|
|
|
17 |
3 |
p. 319-331
|
article
|
| 26 |
Lessons from breast cancer trials of HER2-kinase inhibitors
|
Krop, Ian E
|
|
|
17 |
3 |
p. 267-268
|
article
|
| 27 |
Link between rosacea and glioma in nationwide cohort
|
Bagcchi, Sanjeet
|
|
|
17 |
3 |
p. e94
|
article
|
| 28 |
Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study
|
Yock, Torunn I
|
|
|
17 |
3 |
p. 287-298
|
article
|
| 29 |
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas
|
Froyman, Wouter
|
|
|
17 |
3 |
p. 273-274
|
article
|
| 30 |
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
|
Untch, Michael
|
|
|
17 |
3 |
p. 345-356
|
article
|
| 31 |
Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care
|
Colleoni, Marco
|
|
|
17 |
3 |
p. 265-266
|
article
|
| 32 |
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Chan, Arlene
|
|
|
17 |
3 |
p. 367-377
|
article
|
| 33 |
Neurocognitive functioning and genetic variation in patients with primary brain tumours
|
Wefel, Jeffrey S
|
|
|
17 |
3 |
p. e97-e108
|
article
|
| 34 |
NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
|
Tucker, Helen
|
|
|
17 |
3 |
p. 277-278
|
article
|
| 35 |
NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments
|
Hall, Caroline J
|
|
|
17 |
3 |
p. 279-280
|
article
|
| 36 |
NICE guidance on radium–223 dichloride for hormone–relapsed prostate cancer with bone metastases
|
Umeweni, Nwamaka
|
|
|
17 |
3 |
p. 275-276
|
article
|
| 37 |
Non-clear-cell renal carcinoma therapy: handle with care
|
Buti, Sebastiano
|
|
|
17 |
3 |
p. 270-271
|
article
|
| 38 |
Oncologic Drugs Advisory Committee and conflicts of interest
|
Burki, Talha Khan
|
|
|
17 |
3 |
p. e95
|
article
|
| 39 |
One Hundred Days of Happiness
|
Cagney, Hannah
|
|
|
17 |
3 |
p. 284
|
article
|
| 40 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study
|
Kovács, Gábor
|
|
|
17 |
3 |
p. 332-344
|
article
|
| 41 |
Patient
|
Burki, Talha Khan
|
|
|
17 |
3 |
p. 283
|
article
|
| 42 |
Perceptions of cancer in society must change
|
The Lancet Oncology,
|
|
|
17 |
3 |
p. 257
|
article
|
| 43 |
Prediction of chemotherapy benefit for colon cancers
|
Gilbert, Judith A
|
|
|
17 |
3 |
p. e91
|
article
|
| 44 |
Proton therapy for paediatric medulloblastoma
|
Grosshans, David R
|
|
|
17 |
3 |
p. 258-259
|
article
|
| 45 |
Radiotherapy in patients with connective tissue diseases
|
Giaj-Levra, Niccolò
|
|
|
17 |
3 |
p. e109-e117
|
article
|
| 46 |
REGATTA trial: a call for the USA and Europe
|
D'Ugo, Domenico
|
|
|
17 |
3 |
p. 261-262
|
article
|
| 47 |
Role reversal
|
Murdy, Abigail Grace
|
|
|
17 |
3 |
p. 284
|
article
|
| 48 |
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
|
Antonia, Scott
|
|
|
17 |
3 |
p. 299-308
|
article
|
| 49 |
Tech support
|
Thorley, Jennifer
|
|
|
17 |
3 |
p. 285
|
article
|
| 50 |
The canSAR data hub for drug discovery
|
Chau, Cindy H
|
|
|
17 |
3 |
p. 286
|
article
|
| 51 |
The race for combined checkpoint inhibition in NSCLC
|
Garon, Edward B
|
|
|
17 |
3 |
p. 259-260
|
article
|
| 52 |
Uniformly defining continuous deep sedation
|
Rady, Mohamed Y
|
|
|
17 |
3 |
p. e89
|
article
|
| 53 |
US FDA's safety monitoring of drugs with expedited approval
|
Furlow, Bryant
|
|
|
17 |
3 |
p. 281
|
article
|
Journal description